home / stock / tcda / tcda news

TCDA News and Press, Tricida Inc. From 10/29/20

Stock Information
Company Name: Tricida Inc.
Stock Symbol: TCDA
Market: NASDAQ
Website: tricida.com
Menu
TCDA TCDA Quote TCDA Short TCDA News TCDA Articles TCDA Message Board
Get TCDA Alerts

News, Short Squeeze, Breakout and More Instantly...
TCDA - vTv Therapeutics, Forte Biosciences leads healthcare gainers; Tricida, Cancer Genetics among major losers

Gainers: vTv Therapeutics (VTVT) +22%, Forte Biosciences (FBRX) +20%, Penumbra (PEN) +14%, Cellect Biotechnology (APOP) +10%, Inari Medical (NARI) +10%.Losers: Tricida (TCDA) -52%, Cancer Genetics (CGIX) -34%., Constellation Pharmaceutica...
TCDA - Tricida slumps 46% on FDA feedback on veverimer proposal; launches cost-cutting initiatives

Tricida (TCDA) plummets 46% after announcing an update on its End-of-Review Type A meeting with the FDA. This meeting followed a Complete Response Letter ((CRL)) received by the company in August 2020, for the veverimer NDA that was under FDA review through the Accelerated Approval ...

TCDA - Marvell Technology Group, Credit Suisse Group leads premarket losers' pack

Cancer Genetics (CGIX) -38% after upsized public offering.Tricida (TCDA) -29% after updating its end-of-review Type A meeting with the FDA.Miragen Therapeutics (MGEN) -15%.Nokia (NOK) -16% after Q3 earnings results.CPS Technologies (CPSH) -14% after Q3 earni...

TCDA - Tricida to Provide Update from its End-of-Review Type A Meeting with the FDA

Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced to...
TCDA - Tricida Announces Twelve Data Presentations on Veverimer and Metabolic Acidosis to be Given at the Virtual American Society of Nephrology Kidney Week 2020

Presentations Focus on the Implications of Metabolic Acidosis and CKD Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polyme...

TCDA - Tricida Suffers Setback, And Other News: The Good, Bad And Ugly Of Biopharma

Tricida suffers setback on Veverimer front Tricida Inc. ( TCDA ) reported that the FDA has given a Complete Response Letter to the company for its application pertaining to Veverimer. The New Drug Application for the drug candidate was being reviewed under the Accelerated Approval Progra...

TCDA - IBIO, SHLL, SRNE and NAK among midday movers

Gainers:  Cancer Genetics (NASDAQ: CGIX ) +142% . More news on: Cancer Genetics, Inc., iBio, Inc., Sonnet BioTherapeutics Holdings, Inc., Stocks on the move, , Read more ...

TCDA - FDA rejects Tricida's veverimer for metabolic acidosis in CKD patients

Tricida ( TCDA -14.5% ) has received a Complete Response Letter (CRL) from the FDA regarding its marketing application seeking approval of veverimer (TRC101) for metabolic acidosis in patients with chronic kidney disease (CKD). More news on: Tricida, Inc., Healthcare stocks news, ...

TCDA - Tricida Receives Complete Response Letter from the FDA for its New Drug Application for Veverimer for the Treatment of Metabolic Acidosis and Slowing of Kidney Disease Progression in Patients with Metabolic Acidosis Associated with CKD

Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today th...

TCDA - GOLD, OSTK among premarket gainers

CureVac (NASDAQ: CVAC ) +47%  on making reasonable profit on COVID-19 vaccine. More news on: CureVac N.V., LMP Automotive Holdings, Inc., Microbot Medical Inc., Stocks on the move, , Read more ...

Previous 10 Next 10